Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Chimeric antigen receptor and method for treating liver cancer with same

A chimeric antigen receptor and antigen technology, applied in the field of immunology and medicine, can solve the problems that systemic chemotherapy has not been particularly effective, and advanced or recurrent liver cancer is not very effective

Pending Publication Date: 2019-10-18
DAREN BIOTECH LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Surgery and radiation therapy are options for early-stage liver cancer, but are not very effective for advanced or recurrent liver cancer
Systemic chemotherapy has not become particularly effective and there is a very limited number of drugs available

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chimeric antigen receptor and method for treating liver cancer with same
  • Chimeric antigen receptor and method for treating liver cancer with same
  • Chimeric antigen receptor and method for treating liver cancer with same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0107] Example 2 Expression of NKG2D ligands on various cancer cell lines

[0108] The expression of NKG2D ligands (human MICA / B and human ULBP1-ULBP6) was detected on different cancer cell lines to determine whether the CAR with NKG2D as the antigenic domain could be used to kill these cell lines.

[0109] To detect human MICA / B, 1×10 6 Each cell to be tested was resuspended in 0.5ml PBS buffer and treated with monoclonal mouse anti-human MICA / B (R&D Cat#MAB13001), followed by biotinylated goat anti-mouse IgG (H+L) and streptavidin Primer-APC staining.

[0110] To detect human ULBP2 / 5 / 6, mix 1×10 6 Each cell to be tested was resuspended in 0.5ml PBS buffer and treated with monoclonal mouse anti-human ULBP2 / 5 / 6 (R&D Cat#MAB1298), followed by biotinylated goat anti-mouse IgG(H+L) and streptavidin Avidin-APC staining.

[0111] To detect human ULBP1, 1×10 6 Each cell to be tested was resuspended in 0.5ml PBS buffer and treated with monoclonal mouse anti-human ULBP1 (R&D Cat#...

Embodiment 3

[0118] Example 3 Construction of a lentiviral vector expressing DRCAR

[0119] 1. Construction of pCCL-DRCAR-IRES-DAP10

[0120] pCCL-DRCAR-IRES-DAP10 has as figure 2 The structure shown in A. pCCL-DRCAR-IRES-DAP10 was constructed by the following method.

[0121] Synthetic nucleotide sequences such as image 3 Nucleic acid inserts encoding DRCAR and DAP10 are indicated. The insert fragment includes from the 5' end to the 3' end: 1. HpaI restriction site; 2. EF1α promoter; 3. Kozak; 4. CD33 leader sequence; 5. NKG2D a.a.82-216 fragment; IgG1H in the hinge region; 7. CD28 transmembrane domain; 8. CD28 intracellular signaling domain; 9.4-1BB intracellular signaling domain; 10. CD3ζ intracellular signaling domain; 11. connecting fragment; 12. IRES; 13. Junction fragment; 14. DAP10; 15. Sal I restriction site.

[0122] The above insert fragment and plasmid Pax5 (Addgene, plasmid #35003) were double-digested with restriction endonucleases HpaI and SalI, and the digested prod...

Embodiment 4

[0131] Example 4 DRCAR-T cells kill cancer cells in vitro

[0132] According to the method described in Example 1, T cells were extracted and obtained from human PBMC. Then, the lentivirus containing pCCL-DRCAR-IRES-DAP10 prepared in Example 3 was used to transfect T cells.

[0133] Cytotoxicity assays were performed according to the method described in Example 1 to examine the specific cytotoxic effects of DRCAR-expressing T cells on various tumor cells. Among them, T cells containing pCCL-DRCAR-IRES-DAP10 and T cells not transfected with lentivirus were used as effector cells, and 21 kinds of cancer cells were used as target cells.

[0134] A Raji cell line not expressing NKG2D ligand was used as a negative control.

[0135] The result is as Figure 7 (a)- Figure 7 As shown in (c), under the same experimental conditions, compared with normal T cells without DRCAR, T cells expressing DRCAR were able to induce significantly more target tumor cell death. The tumor cells i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a novel chimeric antigen receptor, an expression vector and a host cell for expressing the chimeric antigen receptor, and application of the chimeric antigen receptor in cancertreatment or preparation of medicines for treating cancers. The chimeric antigen receptor and medicines can be used for treating cancers, such as liver cancer and the like.

Description

[0001] This application claims the priority of the Chinese patent application filed on April 4, 2018 with application number 201810299324.8 and titled "NKG2D Chimeric Antigen Receptor and Its Method for Treating Cancer", the entire contents of which are incorporated herein by reference Applying. technical field [0002] The present invention relates to the fields of immunology and medicine. Specifically, the present invention provides novel chimeric antigen receptors. The present invention also provides the use of the new chimeric antigen receptor in treating cancer or preparing medicine for treating cancer. Background technique [0003] Primary liver cancer is one of the most common forms of cancer in the world. Hepatocellular carcinoma (also known as malignant hepatoma) is the most common form of primary liver cancer and forms within liver cells. Hepatocellular carcinoma occurs mainly in men and in patients suffering from cirrhosis of the liver. Many patients with hepa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/62C12N15/867C12N5/10A61K39/00A61P35/00
CPCA61K39/4611A61K39/464429A61K39/4631C07K14/7051C12N5/0636C12N15/86A61P35/00C07K2319/03C07K2319/33C12N2510/00C12N2740/15043C07K14/7056C07K14/4705A61K2239/38A61K2239/53C12N5/10A61P35/02A61K31/7088C07K19/00C12N15/63A61K38/00C07K14/70517C07K14/70521C07K14/705C12N2740/16043C12N2840/203C07K16/2851A61K2039/844A61K2039/86C07K14/70578
Inventor 谢雍
Owner DAREN BIOTECH LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com